GLP-1s & Weight Loss

Tirzepatide

Educational research reference. This page was restored from the structured compound dataset included with this site export. Protocol examples are context for review and are not medical advice.

At a glance

Route(s)

Subcutaneous

Target

GLP-1; GIP

Timing window

Anytime

Regulatory status

approved drug label available

Protocol context

Standard Protocol

Timeframe	Dose / exposure	Notes
Weeks 1-4	2.5mg once weekly	Initiation phase. Do not skip to avoid severe GI distress.
Weeks 5-8	5.0mg once weekly	Standard therapeutic dose for steady fat loss.
Weeks 9-12	7.5mg once weekly	Escalate only if weight loss stalls.
Weeks 13-16	10.0mg once weekly	Advanced phase.
Weeks 17-20	12.5mg once weekly	Pre-maximum phase.
Weeks 21+	15.0mg once weekly	Maximum limit. Do not exceed.

Alternative: Biohacker Start

Timeframe	Dose / exposure	Notes
Weeks 1-4	1.0mg to 1.5mg once weekly	Lower starting point for highly sensitive subjects.
Weeks 5-8	2.5mg once weekly	Standard initiation.
Weeks 9+	Titrate up by 1.0mg to 2.5mg as needed.	Follows standard protocol from here.

Alternative: Split Dosing

Timeframe	Dose / exposure	Notes
Weeks 1-4	1.25mg every 3.5 days	E.g., Monday and Thursday. Mitigates day-2 lethargy and day-6 appetite return.
Weeks 5-8	2.5mg every 3.5 days	Equals 5.0mg weekly.
Weeks 9-12	3.75mg every 3.5 days	Equals 7.5mg weekly.

Protocol logic

Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (GLP-1; GIP); route Subcutaneous; timing Anytime. Label/trial anchors carry more weight than forum-style escalation. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.

Side effects / cautions listed in dataset

Nausea: most common adverse effect; typically peaks in the first 4 weeks of each dose escalation.
Diarrhea.
Vomiting.
Constipation.
Abdominal pain and cramping.
Dyspepsia (indigestion).
Abdominal distension and bloating.
Decreased appetite and dysgeusia (altered taste).
Belching and flatulence.
Gastroparesis: delayed gastric emptying; may persist even with pre-operative fasting.
Gastroesophageal reflux disease (GERD) exacerbation.
Fatigue and lethargy: frequently secondary to acute caloric deficit.
Day-2 post-injection lethargy: commonly reported phenomenon, particularly in the 12-36 hour window following injection.
Headache.
Dizziness.
Hypoglycemia: risk elevated when combined with insulin or sulfonylureas; rare when used as monotherapy.
Acute pancreatitis: documented in case reports; causal relationship under ongoing investigation.
Acute kidney injury: primarily mediated by dehydration from GI side effects.
Cholelithiasis (gallstones) and acute cholecystitis: risk increases with dose and rate of weight loss.
Diabetic retinopathy complications: risk elevated in subjects with pre-existing retinopathy during rapid glycemic correction.
Thyroid C-cell tumor risk: confirmed in rodent models; human risk remains under evaluation; monitor for neck mass, hoarseness, or dysphagia.
Alopecia (hair loss): reported in post-marketing surveillance.
Injection site reactions: redness, itching, bruising at administration site.
Anaphylaxis and angioedema: rare but documented.
Pulmonary aspiration risk under general anesthesia: secondary to delayed gastric emptying.
Rapid weight regain upon discontinuation: without lifestyle intervention, significant weight rebound is expected within months of cessation.

Contraindications / risk flags listed in dataset

Personal or family history of Medullary Thyroid Carcinoma (MTC).
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Personal or family history of thyroid C-cell tumors.
Active or history of acute pancreatitis.
Severe gastroparesis or clinically significant delayed gastric emptying.
Type 1 diabetes mellitus.
Diabetic ketoacidosis.
Pregnancy: discontinue at least 2 months prior to planned conception; fetal risk not established.
Breastfeeding: insufficient safety data.
Known hypersensitivity or anaphylaxis to tirzepatide or any formulation excipient.
Concurrent use with any other GLP-1 receptor agonist (e.g., semaglutide, liraglutide, dulaglutide): direct pharmacological overlap.
Concurrent use with retatrutide, mazdutide, survodutide, or any other incretin agonist: additive receptor conflict.
History of suicidal ideation or prior suicide attempts: monitor closely.
Planned general anesthesia or elective surgery: delayed gastric emptying significantly raises pulmonary aspiration risk; follow pre-operative fasting and discontinuation protocols.
Severe inflammatory bowel disease or active Crohn's disease: GI motility impairment may worsen symptoms.
End-stage renal disease on dialysis: limited clinical evidence; use with extreme caution.
Pediatric use under age 18: safety and efficacy not established.

Related compounds

Synergistic / related

Cagrilintide AOD-9604 5-Amino-1MQ